Premium
New insights into small‐cell lung cancer development and therapy
Author(s) -
Wang Yuwen,
Zou Songyun,
Zhao Zhuyun,
Liu Po,
Ke Changneng,
Xu Shi
Publication year - 2020
Publication title -
cell biology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.932
H-Index - 77
eISSN - 1095-8355
pISSN - 1065-6995
DOI - 10.1002/cbin.11359
Subject(s) - carboplatin , etoposide , medicine , lung cancer , intensive care medicine , oncology , chemotherapy , immunotherapy , clinical research , cancer , cisplatin
Small‐cell lung cancer (SCLC) accounts for approximately 15% of lung cancer cases; however, it is characterized by easy relapse and low survival rate, leading to one of the most intractable diseases in clinical practice. Despite decades of basic and clinical research, little progress has been made in the management of SCLC. The current standard first‐line regimens of SCLC still remain to be cisplatin or carboplatin combined with etoposide, and the adverse events of chemotherapy are by no means negligible. Besides, the immunotherapy on SCLC is still in an early stage and novel studies are urgently needed. In this review, we describe SCLC development and current therapy, aiming at providing useful advices on basic research and clinical strategy.